Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | Highlights in ADCs for bladder cancer at ASCO 2026

Tian Zhang • 1 Jun 2026
ASCO 2026
Bladder Cancer Genitourinary Cancer Antibodies Enfortumab vedotin Pembrolizumab
EV-302

Tian Zhang, MD, of UT Southwestern Medical Center, discusses key highlights in antibody-drug conjugates (ADCs) for bladder cancer from ASCO 2026, including updated long-term data from the EV-302 trial (NCT04223856) showing durable survival benefits with enfortumab vedotin plus pembrolizumab in metastatic urothelial cancer. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Tian Zhang

Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
3:36
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
Tian Zhang • 1 Jun 2026
BOOST-RCC: evolocumab and nivolumab in metastatic renal cell carcinoma
1:51
BOOST-RCC: evolocumab and nivolumab in metastatic renal cell carcinoma
Tian Zhang • 28 Feb 2026
Overcoming resistance to frontline immunotherapy in kidney cancer
0:57
Overcoming resistance to frontline immunotherapy in kidney cancer
Tian Zhang • 28 Feb 2026

Related Videos

Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
3:36
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
Tian Zhang • 1 Jun 2026
Drug repurposing and trial challenges in rare renal medullary carcinoma
3:11
Drug repurposing and trial challenges in rare renal medullary carcinoma
Pavlos Msaouel • 30 May 2026
Panitumumab-based EGFR blockade in SMARCB1-deficient RMC
2:40
Panitumumab-based EGFR blockade in SMARCB1-deficient RMC
Pavlos Msaouel • 30 May 2026
The content of VJOncology is intended for healthcare professionals